New therapy target to shut down multiple myeloma’s ability to survive and thrive

Multiple myeloma (MM) is one of the most formidable and deadly cancers known to man, with only 50% of patients surviving for more than five years after diagnosis.

Leave A Comment

Your email address will not be published. Required fields are marked *